SCHEMBL17434204

SCHEMBL17434204

C#CCn1c(=O)c2cc(N)ccc2n(CC)c1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.56
▸ KDM4E B2RXH2 3/20 0.56
▸ MAPT P10636 2/20 0.56
▸ GAA P10253 1/20 0.56
▸ GFER P55789 1/20 0.56
▸ KMT2A Q03164 2/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ HPGD P15428 1/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ HTT P42858 1/20 0.48
▸ HBB P68871 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ PARG Q86W56 9/20 0.44
▸ TSHR P16473 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ ADORA2B P29275 2/20 0.39
▸ ADORA3 P0DMS8 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ RAD52 P43351 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17434292 0.95 KDM4E (0.52) ALDH1A1KDM4EMAPTGAAGFER
SCHEMBL17434453 0.87 ALDH1A1 (0.68) ALDH1A1KDM4EMAPTGAAGFER
SCHEMBL17434486 0.81 KDM4E (0.52) ALDH1A1KDM4EMAPTGAAGFER
SCHEMBL17434118 0.80 CYP1A2 (0.65) ALDH1A1MAPTKMT2AMEN1PARG
SCHEMBL17434458 0.80 ALDH1A1 (0.57) ALDH1A1KDM4EMAPTGAAGFER
SCHEMBL17434229 0.80 KDM4E (0.57) ALDH1A1KDM4EMAPTGAAGFER
SCHEMBL17434394 0.80 ALDH1A1 (0.57) ALDH1A1KDM4EMAPTGAAGFER
SCHEMBL17434112 0.80 KDM4E (0.57) ALDH1A1KDM4EMAPTGAAGFER
SCHEMBL17434259 0.79 KDM4E (0.54) ALDH1A1KDM4EMAPTGAAGFER
SCHEMBL17434590 0.78 KDM4E (0.56) ALDH1A1KDM4EMAPTGAAGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9834520-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-12-05 — — US disclosed
US-20160229814-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-08-11 — — US disclosed
EP-2975031-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-01-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160229814-A1 HETEROCYCLIC COMPOUND RORB, RORC, RORA ALDH1A1 312/4885KDM4E 728/4885MAPT 3009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback